Sidoti Equities Analysts Raise Earnings Estimates for Kamada

Key Points

• Sidoti raised Kamada’s FY2026 EPS estimate to $0.46 from $0.43, above the current consensus estimate of $0.44.
• Kamada reported quarterly EPS of $0.16, exceeding expectations by $0.05, while revenue of $54.92 million also topped the $50.84 million consensus forecast.
• The stock opened at $7.26 after rising 5.5%; analysts maintain an overall “Buy” rating with an average price target of $13.00, while institutional investors own 20.38% of shares.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Research analysts at Sidoti lifted their FY2026 earnings estimates for shares of Kamada in a research note issued to investors on Wednesday, August 12th. Sidoti analyst J. Sidoti now expects that the biotechnology company will post earnings per share of $0.46 for the year, up from their prior forecast of $0.43. The consensus estimate for Kamada's current full-year earnings is $0.44 per share.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The business had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.41%.

A number of other analysts have also weighed in on the stock. William Blair set a $15.00 price objective on shares of Kamada in a research note on Tuesday, July 21st. Weiss Ratings downgraded shares of Kamada from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, June 25th. Benchmark restated a "buy" rating on shares of Kamada in a report on Tuesday, July 21st. Finally, Wall Street Zen cut shares of Kamada from a "buy" rating to a "hold" rating in a research report on Saturday, May 23rd. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, Kamada currently has an average rating of "Buy" and an average target price of $13.00.

Kamada Stock Up 5.5%

Shares of NASDAQ KMDA opened at $7.26 on Friday. Kamada has a twelve month low of $6.50 and a twelve month high of $9.35. The firm has a market cap of $417.52 million, a PE ratio of 19.11, a price-to-earnings-growth ratio of 0.63 and a beta of 0.86. The business has a fifty day simple moving average of $7.22 and a two-hundred day simple moving average of $7.96.

Hedge Funds Weigh In On Kamada

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in Kamada by 417.1% in the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 3,862 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kamada in the 4th quarter valued at about $66,000. XTX Topco Ltd purchased a new position in shares of Kamada in the 4th quarter worth approximately $103,000. SIH Partners LLLP bought a new position in shares of Kamada during the 4th quarter worth approximately $134,000. Finally, Quadrature Capital Ltd lifted its position in Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company's stock valued at $155,000 after acquiring an additional 7,627 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company's stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source